Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Indegene Ltd

| Consolidated Financial Results for the Quarter and Year Ended March 31, 2026

Report Source

⬤29th Apr 26

Summary : Company reports strong financial results, strategic acquisitions, and proposes dividend amidst ongoing legal matters.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Total expenses: 30,372 million (FY26) vs 24,072 million (FY25).
  2. Standalone Total expenses: 10,175 million (FY26) vs 9,455 million (FY25).
  3. Consolidated Trade receivables (Billed): 7,702 million (FY26).
  4. Consolidated Trade receivables (Unbilled): 2,116 million (FY26).
  5. Consolidated Revenue from operations: 35,105 million (FY26) vs 28,393 million (FY25).
  6. Standalone Revenue from operations: 12,206 million (FY26) vs 10,936 million (FY25).
  7. Consolidated Net cash from operating activities: 6,508 million (FY26) vs 4,419 million (FY25).
  8. Consolidated Net cash used in investing activities: (5,124) million (FY26) vs (6,827) million (FY25).
  9. Standalone Net cash from operating activities: 3,456 million (FY26) vs 1,290 million (FY25).
  10. Class action lawsuit settlement, provision of 203 million recognized.
  11. Transfer pricing adjustment of 1,114 million, disclosed as contingent liability.
  12. Consolidated Total Assets: 46,203 million (FY26) vs 33,259 million (FY25).
  13. Consolidated Goodwill increased significantly to 11,343 million (FY26) from 3,565 million (FY25).
  14. Standalone Total Assets: 24,819 million (FY26) vs 21,497 million (FY25).
  15. Consolidated Trade receivables (Billed): 7,702 million (FY26) vs 6,322 million (FY25).
  16. Policy on materiality of related party transactions approved.
  17. Both standalone and consolidated financial results are presented.

Corporate Overview

  1. India
  2. Canada
  3. England
  4. Japan
  5. Mexico
  6. Ireland
  7. Germany
  8. Singapore
  9. Switzerland
  10. China
  11. Austria
  12. Class action lawsuit regarding TCPA violations.
  13. Potential transfer pricing adjustments from tax authorities.
  14. Reliance on external legal advice for litigation and tax matters.
  15. Global presence with parent, wholly-owned, and step-down subsidiaries.
  16. Reorganized into Enterprise Medical Solutions and Enterprise Commercial Solutions segments.
  17. Acquisitions to strengthen commercialization portfolio and expand market reach.
  18. Integrates advanced AI and digital advertising technologies.
  19. Confident in financial performance and strategic direction.
  20. Proactive in addressing legal and regulatory matters.
  21. Pharmaceutical and biotech companies (for marketing campaigns).
  22. Enterprise Medical Solutions
  23. Enterprise Commercial Solutions
  24. Others (consultancy and clinical business)
  25. Growth in revenue and strategic acquisitions indicate expanding operations.
  26. Utilized IPO proceeds for capital expenditure.
  27. Investments in technology, cybersecurity, and cloud infrastructure.
  28. Strategic acquisitions for inorganic growth and market expansion.

Risk Factors

  1. Ongoing class action lawsuit settlement.
  2. Potential transfer pricing tax adjustments.
  3. Integration risks from recent acquisitions.
  4. Compliance with new Labour Codes.

Key Drivers

  1. Strong financial performance and revenue growth.
  2. Strategic acquisitions expanding market reach.
  3. Proposed dividend signals financial health.
  4. Investments in technology and infrastructure.

Auditor’s Report

  1. Unmodified opinion on consolidated financial results.
  2. Unmodified opinion on standalone financial results.

Board Commentary

  1. Approved allotment under ESOP Scheme 2020 and RSU Scheme 2020.
  2. Approved amendments to various policies including Board diversity, NED payment criteria, Code of Conduct, Materiality, ID terms, CSR, Risk Management, Dividend Distribution, POSH, Investor Interaction, Records Archival.
  3. Recommended final dividend of Rs. 2.25 per equity share for FY26.
  4. Class action lawsuit with potential settlement costs.
  5. Transfer pricing adjustments by tax authorities.
  6. Class action lawsuit for TCPA violations, provision of 203 million recognized.
  7. Draft transfer pricing order proposing 1,114 million adjustment, disclosed as contingent liability.
  8. New Labour Codes assessed with no material financial impact.
  9. IPO proceeds utilized for debt repayment, capital expenditure, technology, cybersecurity, and inorganic growth.
  10. Unutilized IPO proceeds of 172 million remain.

Corporate Governance

  1. Whistle Blower Policy.
  2. Code of conduct for prevention of insider trading.
  3. Code of practices and procedures for fair disclosure of UPSI.
  4. Policy on Evaluation of the performance of the Board of Directors.
  5. Policy on Terms and Conditions of Independent Directors.
  6. Policy for familiarization program for Independent Directors.

Management Discussion & Analysis

Future Strategy

  1. Continue inorganic growth through strategic acquisitions.
  2. Expand healthcare marketing and communication capabilities in Europe.
  3. Integrate advanced AI and digital advertising technologies.

Industry Overview

  1. Healthcare marketing and communication industry, integrating AI/digital advertising.

Operational Focus Areas

  1. Ensuring compliance with new Labour Codes.
  2. Resolving legal and regulatory challenges.

Performance Drivers

  1. Strong revenue growth in Enterprise Commercial Solutions.
  2. Strategic acquisitions contributing to overall growth.
  3. Effective utilization of IPO proceeds for expansion.

Risk Control Measures

  1. Provision recognized for class action lawsuit.
  2. Contesting transfer pricing adjustments through MAP process.
  3. Assessing impact of new Labour Codes, no material impact expected.

Critical Risks

  1. Class action lawsuit settlement costs.
  2. Unfavorable outcome of transfer pricing adjustments.
  3. Integration challenges of acquired entities.